Terns Pharmaceuticals to Present at Upcoming Investor Conferences
August 03 2021 - 4:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, today announced that
management will be participating in a liver disease panel at the
2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at
2:20pm ET. Terns management will also present at the Canaccord
Genuity 41st Annual Growth Conference on Wednesday, August 11 at
1:00pm ET.
A live webcast of the events will be available on the investor
relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcasts will be
archived on Terns’ website for 30 days following the
presentations.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates for the treatment of non-alcoholic
steatohepatitis, or NASH, and other chronic liver diseases. Terns’
pipeline includes three clinical stage development programs
including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist,
and a preclinical GLP-1 receptor agonist program. Terns is focused
on developing combination therapies based on clinically validated
and complementary mechanisms of action to address the multiple
hepatic disease processes of NASH in order to drive meaningful
clinical benefits for patients. For more information, please visit:
www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Sep 2023 to Sep 2024